Alexza to Report 2013 Third Quarter Financial Results on Wednesday, November 6, 2013

 Alexza to Report 2013 Third Quarter Financial Results on Wednesday, November
                                   6, 2013

PR Newswire

MOUNTAIN VIEW, Calif., Oct. 16, 2013

MOUNTAIN VIEW, Calif., Oct. 16, 2013 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended September
30, 2013 on Wednesday, November 6, 2013, following the close of the U.S.
financial markets. The Company will also host an investor conference call and
live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific
Time to provide a company update and discuss the financial results.

To access the webcast via the Internet, go to www.alexza.com, under the
"Investor Relations" link. Please log onto the webcast prior to the start of
the call to ensure time for any software downloads that may be required to
participate in the webcast.

To access the live conference call, dial 888-680-0879 or +1-617-213-4856
(international). The reference number to enter the call is 95388115.
Interested parties may also pre-register for the call at
https://www.theconferencingservice.com/prereg/key.process?key=PK46KVA67.

A replay of the conference call may be accessed at www.alexza.com under the
"Investor Relations" link, or by dialing 888-286-8010 or +1-617-801-6888
(international). The reference number for the replay of the call is
37910049. A replay of the call will be available for 30 days following the
event.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato^® system,
a hand-held inhaler designed to deliver a drug aerosol to the deep lung,
providing rapid systemic delivery and therapeutic onset, in a simple,
non-invasive manner.

ADASUVE^® (Staccato loxapine), Alexza's first approved product, was approved
by the U.S. Food and Drug Administration in December 2012 and by the European
Medicines Agency in February 2013. Teva Pharmaceuticals USA, Inc. is Alexza's
commercial partner for ADASUVE in the U.S. Grupo Ferrer Internacional, S.A.
is Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia
and the Commonwealth of Independent States countries.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit www.alexza.com. For more
information about ADASUVE, please visit www.adasuve.com.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,
Inc.

Safe Harbor Statement
The anticipated news release and conference call will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of 1995,
and should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of Alexza and our
partners, Teva and Ferrer, to effectively and profitably commercialize
ADASUVE, estimated product revenues and royalties associated with the sale of
ADASUVE, the adequacy of the Company's capital to support the Company's
operations, and the Company's ability to raise additional funds and the
potential terms of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect, would cause
its results to differ materially from those expressed or implied by such
forward-looking statements. These and other risks concerning Alexza's business
are described in additional detail in the Company's Annual Report on Form 10-K
for the year ended December 31, 2012 and the Company's other Periodic and
Current Reports filed with the Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made as of this
date, and the Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Website: http://www.alexza.com
Contact: BCC Partners: Karen L. Bergman or Michelle Corral, 650.575.1509 or
415.794.8662, kbergman@bccpartners.com or mcorral@bccpartners.com